查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1338912

苹果酸舒尼替尼市场、份额、规模、趋势、产业分析报告：按应用；按地区；细分市场预测，2023-2032 年

Sunitinib Malate Market Share, Size, Trends, Industry Analysis Report, By Application (Pancreatic Neuroendocrine Tumor, Kidney Cancer, Gastro-intestinal Stromal Tumor); By Region; Segment Forecast, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球苹果酸舒尼替尼市场规模预计将达到2.7854亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

FDA 批准苹果酸舒尼替尼和其他标靶癌症治疗药物可能会积极影响投资者对製药业的信心。 在癌症研究领域，2022 年出现了一些重大进展。 美国食品药物管理局 (FDA) 已批准 40 种用于癌症适应症的药物，其中 12 种是从未在人类中使用过的全新分子。 最近的一篇部落格文章提供了前几年 FDA 批准的清单。 这可能会导致研发投资增加，从而发现新的癌症治疗方法，进一步推动市场成长。

在全球范围内，癌症是导致死亡的主要原因之一，也是苹果酸舒尼替尼市场成长的主要原因。 苹果酸舒尼替尼用于治疗某些类型的癌症，包括肾细胞癌和胃肠道间质瘤，全球癌症发病率不断上升正在推动抗癌药物的需求，我们正在推广它。 据世界卫生组织 (WHO) 称，癌症是全球头号死亡原因，预计 2020 年将有 1,930 万新发病例和 1,000 万癌症相关死亡。 由于老化、生活方式的改变和环境因素等因素，癌症的发生率预计将继续增加。

已开发国家和新兴国家医疗保健支出的增加预计将推动苹果酸舒尼替尼市场的成长。 医疗保健支出的增加是由于多种因素造成的，包括人口老化、慢性病盛行率上升以及政府不断采取措施改善癌症照护。 根据2022年11月更新的资料库“OECD Health Data 2022”，20个国家的初步估计显示，2021年医疗费用平均成长约6%。

新的和创新的癌症治疗方法的开发，包括苹果酸舒尼替尼等标靶疗法，正在推动市场成长。 与传统化疗相比，这些治疗方法具有更高的疗效和更少的副作用。 据美国癌症研究协会称，由于过去几十年癌症研究和治疗的发展，到 2022 年初，美国癌症倖存者人数将超过预测的 1800 万人。 儘管癌症检测和治疗取得了进展，但要减轻可预防癌症的负担，仍有许多工作要做。

苹果酸舒尼替尼市场报告亮点

由于胰臟神经内分泌肿瘤盛行率不断增加，胰臟神经内分泌肿瘤领域占比较高。

北美癌症发生率较高，因此预期会有较高的成长和较大的销售份额。

由于老年人口不断增长，预计欧洲在研究期间将占据第二大销售份额。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球苹果酸舒尼替尼市场洞察

  • 苹果酸舒尼替尼市场 - 产业概况
  • 苹果酸舒尼替尼市场动态
    • 推动者和机会
      • 对有效癌症治疗的需求不断增加
      • 政府对医疗保健基础设施的投资
    • 抑制因素和挑战
  • 杵分析
  • 价值链分析
  • 苹果酸舒尼替尼产业趋势
  • COVID-19 感染的影响分析

第五章全球苹果酸舒尼替尼市场，依应用划分

  • 主要发现
  • 简介
  • 胰臟神经内分泌肿瘤
  • 肾癌
  • 胃肠道间质瘤

第 6 章全球苹果酸舒尼替尼市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年苹果酸舒尼替尼市场评估（按地区）
  • 苹果酸舒尼替尼市场 - 北美
    • 北美：苹果酸舒尼替尼市场，依应用划分，2019-2032 年
    • 苹果酸舒尼替尼市场 - 美国
    • 苹果酸舒尼替尼市场 - 加拿大
  • 苹果酸舒尼替尼市场 - 欧洲
    • 欧洲：苹果酸舒尼替尼市场，依应用划分，2019-2032 年
    • 苹果酸舒尼替尼市场 - 英国
    • 苹果酸舒尼替尼市场 - 法国
    • 苹果酸舒尼替尼市场 - 德国
    • 苹果酸舒尼替尼市场 - 义大利
    • 苹果酸舒尼替尼市场 - 西班牙
    • 苹果酸舒尼替尼市场 - 荷兰
    • 苹果酸舒尼替尼市场 - 奥地利
  • 苹果酸舒尼替尼市场 - 亚太地区
    • 亚太地区：苹果酸舒尼替尼市场，依应用划分，2019-2032 年
    • 苹果酸舒尼替尼市场 - 中国
    • 苹果酸舒尼替尼市场 - 印度
    • 苹果酸舒尼替尼市场 - 马来西亚
    • 苹果酸舒尼替尼市场 - 日本
    • 苹果酸舒尼替尼市场 - 印度尼西亚
    • 苹果酸舒尼替尼市场 - 韩国
  • 苹果酸舒尼替尼市场 - 中东和非洲
    • 中东和非洲：苹果酸舒尼替尼市场，按应用划分，2019-2032 年
    • 苹果酸舒尼替尼市场 - 沙乌地阿拉伯
    • 苹果酸舒尼替尼市场 - 阿拉伯联合大公国
    • 苹果酸舒尼替尼市场 - 以色列
    • 苹果酸舒尼替尼市场 - 南非
  • 苹果酸舒尼替尼市场 - 拉丁美洲
    • 拉丁美洲：苹果酸舒尼替尼市场，按应用划分，2019-2032 年
    • 苹果酸舒尼替尼市场 - 墨西哥
    • 苹果酸舒尼替尼市场 - 巴西
    • 苹果酸舒尼替尼市场 - 阿根廷

第七章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第八章公司简介

  • Pfizer
  • Top Care Pharmacy
  • J&K Scientific
  • Targetmol
  • Active Biotech
  • Astellas Pharma
  • AstraZeneca
  • Bristol Myers Squibb
  • Dendreon
  • Endo International
  • Ferring Pharmaceuticals
Product Code: PM3356

The global sunitinib malate market size is expected to reach USD 278.54 Million by 2032, according to a new study by Polaris Market Research. The report "Sunitinib Malate Market Share, Size, Trends, Industry Analysis Report, By Application (Pancreatic Neuroendocrine Tumor, Kidney Cancer, Gastrointestinal Stromal Tumor); By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The FDA's approval of sunitinib malate and other targeted cancer therapies can have a positive impact on investor confidence in the pharmaceutical industry. In the area of cancer research, 2022 saw some significant advancements. For oncology indications, the U.S. Food and Drug Administration (FDA) approved 40 drugs, 12 of which were brand-new molecules that had never been used in humans before. A recent blog post lists the FDA approvals from the previous year. This can lead to increased investment in research and development, which can lead to the discovery of new cancer treatments and further drive the growth of the market.

Globally, cancer is one of the leading causes of death and the primary cause of growth in the sunitinib market. Sunitinib Malate is used in the treatment of certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors, and the increasing incidence of cancer worldwide is driving the demand for cancer therapies. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with an estimated 19.3 million new cases and 10 million cancer-related deaths in 2020. The incidence of cancer is expected to continue to increase in the coming years, driven by factors such as an aging population, lifestyle changes, and environmental factors.

The increasing healthcare expenditure in developed and developing countries is expected to drive the growth of the sunitinib malate market. The rise in healthcare expenditure is due to various factors such as the aging population, rising prevalence of chronic diseases, and increasing government initiatives to improve cancer care. The database OECD Health Data 2022, updated in November 2022, states that preliminary estimates for a group of 20 countries indicate that health spending rose by about 6% on average in 2021.

The development of new and innovative cancer treatments, including targeted therapies such as sunitinib malate, is driving the growth of the market. These therapies offer improved efficacy and fewer side effects compared to traditional chemotherapy. According to the American Association for Cancer Research, early in 2022, there will be more cancer survivors in the United States than the predicted 18 million, due to developments in cancer research and treatment over the previous decades. There is still much to be done to lessen the burden of preventable cancer, despite the advancements it has achieved in the detection and treatment of the disease.

Sunitinib Malate Market Report Highlights

Pancreatic Neuroendocrine Tumor segment accounted for the higher growth rate owing to the increasing incidence of PNET.

North America is projected to experience higher growth and larger revenue share due to the high prevalence of cancer.

Europe is expected to registered with the second-largest revenue share in the study period due to the growing elderly population.

The global players include: Pfizer, Top Care Pharmacy, J&K Scientific, Targetmol, Active Biotech, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Dendreon, Endo International & Ferring Pharmaceuticals.

Polaris Market Research has segmented the sunitinib malate market report based on application and region:

Sunitinib Malate, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Pancreatic Neuroendocrine Tumor
  • Kidney Cancer
  • Gastrointestinal Stromal Tumor
  • Sunitinib Malate, Regional Outlook (Revenue - USD Million, 2019 - 2032
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Sunitinib Malate Market Insights

  • 4.1. Sunitinib Malate Market - Industry Snapshot
  • 4.2. Sunitinib Malate Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing demand for effective cancer treatments
      • 4.2.1.2. Government investment in healthcare infrastructure
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Value Chain Analysis
  • 4.6. Sunitinib Malate Industry trends
  • 4.7. COVID-19 Impact Analysis

5. Global Sunitinib Malate Market, by Application

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • 5.3. Pancreatic Neuroendocrine Tumor
    • 5.3.1. Global Sunitinib Malate Market, by Pancreatic Neuroendocrine Tumor, by Region, 2019-2032 (USD Million)
  • 5.4. Kidney Cancer
    • 5.4.1. Global Sunitinib Malate Market, by Kidney Cancer, by Region, 2019-2032 (USD Million)
  • 5.5. Gastrointestinal Stromal Tumor
    • 5.5.1. Global Sunitinib Malate Market, by Gastrointestinal Stromal Tumor, by Region, 2019-2032 (USD Million)

6. Global Sunitinib Malate Market, by Geography

  • 6.1. Key findings
  • 6.2. Introduction
    • 6.2.1. Sunitinib Malate Market Assessment, By Geography, 2019-2032 (USD Million)
  • 6.3. Sunitinib Malate Market - North America
    • 6.3.1. North America: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.3.2. Sunitinib Malate Market - U.S.
      • 6.3.2.1. U.S.: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.3.3. Sunitinib Malate Market - Canada
      • 6.3.3.1. Canada: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • 6.4. Sunitinib Malate Market - Europe
    • 6.4.1. Europe: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.2. Sunitinib Malate Market - UK
      • 6.4.2.1. UK: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.3. Sunitinib Malate Market - France
      • 6.4.3.1. France: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.4. Sunitinib Malate Market - Germany
      • 6.4.4.1. Germany: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.5. Sunitinib Malate Market - Italy
      • 6.4.5.1. Italy: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.6. Sunitinib Malate Market - Spain
      • 6.4.6.1. Spain: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.7. Sunitinib Malate Market - Netherlands
      • 6.4.7.1. Netherlands: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.4.8. Sunitinib Malate Market - Austria
      • 6.4.8.1. Austria: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • 6.5. Sunitinib Malate Market - Asia Pacific
    • 6.5.1. Asia Pacific: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.2. Sunitinib Malate Market - China
      • 6.5.2.1. China: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.3. Sunitinib Malate Market - India
      • 6.5.3.1. India: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.4. Sunitinib Malate Market - Malaysia
      • 6.5.4.1. Malaysia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.5. Sunitinib Malate Market - Japan
      • 6.5.5.1. Japan: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.6. Sunitinib Malate Market - Indonesia
      • 6.5.6.1. Indonesia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.5.7. Sunitinib Malate Market - South Korea
      • 6.5.7.1. South Korea: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • 6.6. Sunitinib Malate Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.6.2. Sunitinib Malate Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.6.3. Sunitinib Malate Market - UAE
      • 6.6.3.1. UAE: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.6.4. Sunitinib Malate Market - Israel
      • 6.6.4.1. Israel: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.6.5. Sunitinib Malate Market - South Africa
      • 6.6.5.1. South Africa: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • 6.7. Sunitinib Malate Market - Latin America
    • 6.7.1. Latin America: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.7.2. Sunitinib Malate Market - Mexico
      • 6.7.2.1. Mexico: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.7.3. Sunitinib Malate Market - Brazil
      • 6.7.3.1. Brazil: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
    • 6.7.4. Sunitinib Malate Market - Argentina
      • 6.7.4.1. Argentina: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. Pfizer
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. Top Care Pharmacy
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. J&K Scientific
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. Targetmol
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. Active Biotech
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. Astellas Pharma
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. AstraZeneca
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Bristol Myers Squibb
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Dendreon
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Endo International
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development
  • 8.11. Ferring Pharmaceuticals
    • 8.11.1. Company Overview
    • 8.11.2. Financial Performance
    • 8.11.3. Product Benchmarking
    • 8.11.4. Recent Development

List of Tables

  • Table 1 Global Smart Railway Market, by Application, 2019-2032 (USD Million)
  • Table 2 Sunitinib Malate Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 3 North America: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 4 U.S.: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 5 Canada: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 6 Canada: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 7 Europe: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 8 Spain: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 9 Netherlands: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 10 Austria: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 11 Germany: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 12 Italy: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 13 France: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 14 Asia Pacific: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 15 China: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 16 Japan: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 17 India: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 18 Indonesia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 19 South Korea: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 20 Malaysia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 21 Latin America: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 22 Brazil: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 23 Mexico: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 24 Argentina: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 25 Middle East & Africa: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 26 South Africa: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 27 Israel: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 28 Saudi Arabia: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)
  • Table 29 UAE: Sunitinib Malate Market, by Application, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global Sunitinib Malate Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Application
  • Figure 7 Global Sunitinib Malate Market, by Application, 2022 & 2032 (USD Million)
  • Figure 8 Sunitinib Malate Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 9 Strategic Analysis - Sunitinib Malate Market